AVP-receptor antagonists represent a promising therapeutic advance for treating dilutional hyponatremia in psychiatric patients.
No takes yet. Share an insight, caveat, or question.
Supports AVP antagonists for schizophrenia hyponatremia; leaves open randomized confirmation before practice change.
Arthur J. Siegel (2008) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: